Tesamorelin dosage: the approved 2mg protocol, explained

Last updated 2026-07-24

What is the standard tesamorelin dosage?

The dose used in the trials that got tesamorelin (brand name Egrifta, and later Egrifta SV) approved by the FDA is 2mg injected subcutaneously once a day, typically in the abdomen. That's it. That's the whole dosing story for the approved indication, which is reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The pooled phase 3 data (two multicenter, double-blind, placebo-controlled trials with a safety extension) used this exact regimen and is the backbone of everything we know about tesamorelin's efficacy and safety in humans ^[1]. A 2010 review in the Journal of Clinical Endocrinology and Metabolism describes the pooled analysis showing measurable visceral adipose tissue (VAT) reduction at this dose over 26 weeks, with effects sustained in patients who continued into the extension phase ^[1]. Everything you read online about "tesamorelin dosage for bodybuilding" or higher-dose protocols is extrapolation, not trial evidence. No published randomized controlled trial has tested tesamorelin at doses meaningfully above 2mg/day in a way that changes this answer. If you're comparing tesamorelin against other peptides for off-label use, know that the evidence quality drops off a cliff outside this one indication.

How is a 2mg tesamorelin vial mixed and dosed?

A standard 2mg vial of tesamorelin is a lyophilized (freeze-dried) powder that needs reconstitution with bacteriostatic water before injection. The core math: draw up a fixed volume of water, and that determines the concentration, which determines how many units you draw for a 2mg dose. Common reconstitution volumes people use are 1mL, 2mL, or 2.5mL of bacteriostatic water per 2mg vial. At 1mL, you get 2mg/mL, meaning the full dose is drawn to the 100-unit mark on a standard insulin syringe (100 units = 1mL). At 2mL, concentration drops to 1mg/mL, so a full 2mg dose needs 2mL, or you'd draw 100 units twice, which isn't practical for a single injection, so most people reconstitute closer to 1mL to 1.5mL for a 2mg vial specifically to keep injection volume reasonable. This is exactly the kind of arithmetic that trips people up and where a dedicated tesamorelin dosage calculator or a walkthrough on tesamorelin reconstitution earns its keep. Get the concentration wrong and you either underdose (no effect, wasted vial) or overdose (more side effects, no added benefit based on trial data). Once mixed, tesamorelin is not shelf-stable indefinitely. Refrigerate it, protect it from light, and don't use it past the manufacturer's stated in-use window, generally measured in days to a few weeks depending on the product labeling, not months.

What about tesamorelin 5mg dosage or larger multi-dose vials?

Some compounded or research-labeled products come in 5mg or 10mg vial sizes rather than the 2mg size used in the original trials. These are not different drugs, they're the same peptide at a different total mass per vial, meant to be reconstituted to a larger volume so you can pull multiple 2mg (or whatever your target) doses from one vial over several days. For a tesamorelin 5mg vial, a common approach is reconstituting with 2.5mL of bacteriostatic water to get 2mg/mL, so a 1mL draw delivers a 2mg dose, matching the trial regimen. For a tesamorelin 10mg vial, reconstituting with 5mL gets you the same 2mg/mL concentration, useful if you want fewer reconstitution cycles per month. The practical upside of larger vials is cost per dose and fewer needle punctures into the septum. The downside is more room for math errors, and a longer window where the reconstituted solution sits in the fridge, which is more days of potential degradation or contamination risk if sterile technique slips. If you're unsure which vial size and dilution combination gets you to a clean 2mg dose, that's worth working out on paper before you draw anything into a syringe, and it's a big part of why we built a tesamorelin dosage calculator.

Tesamorelin dosage chart: vial size, dilution, and dose per unit

Here's the math laid out so you're not doing it under time pressure at the kitchen counter. | Vial size | BAC water added | Concentration | Dose target | Volume to draw | Insulin syringe units |

How often do you inject tesamorelin, and when?

In the phase 3 trials, tesamorelin was dosed once daily, every day, generally in the evening ^[1]. That daily frequency, not weekly or every-other-day, is what the approved label and the underlying efficacy and safety data reflect. There's a physiological reason behind the daily schedule rather than it being arbitrary. Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue, and it works by stimulating the pituitary to release growth hormone in a pattern that mimics natural pulsatile secretion ^[2]. Spacing doses out further than studied changes that pulsatile exposure in ways nobody has trial data on. Population pharmacokinetic modeling of tesamorelin in both HIV-infected patients and healthy subjects found the drug's clearance and distribution behave consistently enough across populations to support the once-daily regimen used in registration trials, without needing dose adjustment based on most demographic factors studied ^[3]. That's a pharmacokinetics paper, not a dosing guideline on its own, but it's the closest thing we have to formal justification for the schedule beyond "this is what was tested."

Is there a tesamorelin dosage for bodybuilding or general fat loss?

No validated one exists. The approved dose (2mg/day) was studied specifically in HIV-associated lipodystrophy patients with excess abdominal visceral fat, not in healthy athletes or people using it for aesthetic or performance goals ^{[1] [4]}. A 2026 review in the Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews looked at therapeutic peptides broadly in orthopaedic contexts and flags the general challenge across this drug class: strong mechanistic rationale for peptides like GHRH analogues doesn't automatically translate into validated protocols outside the populations where they were actually tested ^[5]. A companion piece in The American Journal of Sports Medicine, aimed at sports medicine physicians, makes a similar point when surveying injectable peptide therapies used off-label in athletic populations: the gap between mechanism and trial-backed dosing in athletic or bodybuilding contexts is real and not fully closed ^[6]. A broader 2026 paper in Sports Medicine reviewing approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance covers this exact tension: tesamorelin has one FDA-approved use, and any use for muscle gain, fat loss in non-lipodystrophy patients, or recovery is off-label extrapolation without dedicated trials to define a safe or effective dose for that purpose ^[7]. If you're bodybuilding-curious about tesamorelin because you've heard it helps with visceral fat, understand that the visceral fat evidence is specifically from HIV lipodystrophy patients, a population with a distinct metabolic and fat-distribution profile from a healthy lifter's. Extrapolating the 2mg dose to a different population and a different goal is a real gap, not a technicality.

What did the phase 3 trials actually measure at this dose?

The pooled phase 3 analysis, covering two multicenter, double-blind, placebo-controlled trials plus a safety extension, is the single most important piece of tesamorelin evidence there is, and it all used the 2mg/day dose ^[1]. It measured visceral adipose tissue by CT scan, more than waist circumference, giving a harder endpoint than most fat-loss studies bother with. Separately, a 2017 study in AIDS found that visceral fat reduction with tesamorelin correlated with improved liver enzymes in HIV patients, tying the VAT change to a downstream metabolic marker rather than just a cosmetic measurement ^[8]. A 2019 randomized, double-blind, multicenter trial published in The Lancet HIV went further and looked at tesamorelin's effect on non-alcoholic fatty liver disease (NAFLD) in HIV patients specifically, again at the same daily-dosing approach ^[9]. A 2021 study in AIDS reported that tesamorelin improves fat quality independent of changes in fat quantity, meaning some of the metabolic benefit isn't purely about how much fat comes off, but how the remaining fat behaves metabolically ^[10]. That's a subtler finding than "visceral fat went down X%" and worth knowing if you're expecting dosage changes to produce linear, purely cosmetic results. More recent work has kept testing the same dosing framework in adjacent questions. A 2024 study in AIDS looked at efficacy and safety of tesamorelin in people with HIV on integrase inhibitors, a drug class widely used now that wasn't as dominant when the original trials ran, and found the drug's effect profile held up in that updated treatment context ^[11]. A 2025 paper in the Journal of Infectious Diseases examined tesamorelin's effects on neurocognitive impairment in people with HIV and abdominal obesity, again using the same established dosing approach as a study variable rather than testing new doses ^[12].

Does tesamorelin dosage need adjustment for kidney or liver function?

This is a real gap in the public dosing conversation, and it's worth being honest about it: dedicated dose-adjustment schedules for renal or hepatic impairment aren't laid out in detail in the sources reviewed here. The population pharmacokinetic analysis modeled tesamorelin's behavior across HIV-infected patients and healthy subjects and is the most relevant PK data available for understanding how consistently the drug clears across different patient profiles ^[3], but it isn't a substitute for a clinician's individualized judgment if you have significant kidney or liver disease. Given that tesamorelin's approved use already sits inside a population (HIV-associated lipodystrophy) that frequently has metabolic comorbidities, including elevated liver fat, this is exactly the kind of decision that belongs with a prescriber who can review labs, not something to self-adjust based on a forum post. If your liver or kidney function is a known issue, that's a conversation for whoever is reviewing your case for a prescription, not a dose you tweak on your own.

What if tesamorelin dosage misses a day or a dose is skipped?

There isn't a published trial protocol for handling missed doses because the phase 3 studies were designed around consistent daily administration, not around modeling what happens after a gap ^[1]. The honest answer is that occasional missed doses in a long-running daily GHRH analogue regimen are unlikely to undo months of visceral fat change, but there's no dedicated study quantifying exactly how much a missed dose, or several, blunts the outcome. What's clearer is the opposite mistake: doubling up to "catch up" isn't supported by any of the dosing evidence reviewed here and isn't how the drug was studied. If you miss a dose, the safer default, absent a specific instruction from whoever is managing your prescription, is to resume the normal daily schedule rather than stacking doses.

How does tesamorelin dosage compare with other GHRH-class peptides?

Tesamorelin is distinct from other GHRH analogues and growth hormone secretagogues you'll see discussed alongside it (like sermorelin or CJC-1295) in that it's the one with FDA approval and a phase 3 evidence base behind a specific daily dose ^{[4] [2]}. A 2011 Nature Reviews Drug Discovery profile of tesamorelin frames it plainly as a GHRH analogue developed and approved specifically for reducing excess visceral fat in HIV lipodystrophy, a narrower regulatory story than most peptides in this space get ^[2]. A 2011 review in Drugs covering tesamorelin's role in managing HIV-associated lipodystrophy, and a companion 2012 review in The Annals of Pharmacotherapy, both describe the same 2mg daily regimen as the basis for the drug's approved use, reinforcing that this dose isn't one option among several tested doses, it's the dose ^{[13] [14]}. A 2011 BioDrugs "spotlight" review covers the same ground with a focus on the drug's practical clinical adoption at this dosing level ^[15]. If you're weighing tesamorelin against unapproved GHRH peptides sold without FDA review, the dosage-evidence gap is the whole story: tesamorelin has a number (2mg/day) tied to CT-scan-measured outcomes in randomized trials. Most other GHRH-class products in the peptide space don't have anything close to that.

What are the practical mixing and storage rules for tesamorelin?

Beyond getting the milligram math right, a few practical rules matter more than people expect. Use bacteriostatic water, not plain sterile water, for reconstitution, since the preservative in bacteriostatic water helps the mixed solution stay usable for longer instead of requiring single-use discard. Inject subcutaneously (into fat under the skin, typically the abdomen), not intramuscularly, matching how the phase 3 trials administered the drug ^[1]. Rotate injection sites within the abdominal area to reduce local irritation. Refrigerate the reconstituted vial and keep it away from light. Don't use a vial that looks cloudy, discolored, or has visible particles, and don't use it past whatever in-use dating applies to your specific product. If you're switching between a 2mg vial and a 5mg or 10mg vial size, redo the concentration math each time rather than assuming your old draw volume still applies, since that's one of the more common dosing mistakes people make when they upgrade to a larger vial for cost reasons. For the step-by-step version of this, with syringe-by-syringe walkthroughs, see our dedicated guide on tesamorelin reconstitution.

What does the tesamorelin dosage evidence not cover?

It's worth being blunt about the edges of this evidence base, because a lot of what circulates about tesamorelin dosing goes well past what's actually been tested. The approved dose and its supporting trials are specific to HIV-associated lipodystrophy with excess abdominal fat, studied with CT-measured visceral adipose tissue as a primary endpoint ^{[1] [4]}. There is no dedicated phase 3 trial establishing an effective or safe dose for general population fat loss, anti-aging use, athletic performance, or bodybuilding, and the sports medicine literature reviewing peptide use in these contexts says as much directly ^{[5] [6] [7]}. A 2022 review in The Journal of Clinical Endocrinology and Metabolism on approaching patients with lipodystrophy situates tesamorelin within a broader diagnostic and treatment framework for lipodystrophy syndromes generally, which is useful context but again centers on a specific clinical population rather than general dosing guidance for healthy adults ^[16]. A related 2012 paper in Annales d'Endocrinologie on diagnosing lipodystrophy syndromes reinforces that lipodystrophy is a defined clinical diagnosis, not a loose descriptor for stubborn abdominal fat in an otherwise healthy person ^[17]. A 2026 meta-analysis in Obesity Research & Clinical Practice pooling randomized controlled trials of tesamorelin in HIV-associated lipodystrophy is the most recent synthesis of body composition, hepatic fat, metabolic, and safety outcomes at the studied dosing regimen, and it's a good marker of just how much of the evidence base sits inside this one indication ^[18]. If your reason for wanting a tesamorelin dose is anything other than that indication, you're in off-label territory, and it's worth understanding that clearly before deciding what to do.

How do you actually get a legitimate tesamorelin dose?

Tesamorelin, as Egrifta or Egrifta SV, is an FDA-approved prescription drug, not an over-the-counter research chemical, which means a legitimate dosing plan starts with a prescriber evaluating whether you have an approved or medically reasonable off-label indication ^[4]. Compounded versions exist too, since tesamorelin appears in FDA's bulk drug substance frameworks governing what pharmacies can compound under sections 503A and 503B of the Food, Drug and Cosmetic Act ^{[19] [20]}. Compounding under 21 U.S.C. 353a allows licensed pharmacies to prepare patient-specific formulations, including different vial sizes and concentrations than the brand-name product, which is part of why 5mg and 10mg vials circulate alongside the original 2mg format ^[21]. Whatever route you take, dosage decisions, vial size, and reconstitution protocol should go through a provider-reviewed process rather than guesswork against a forum-sourced chart. If you're figuring out where a prescription-based, provider-reviewed path fits into your plan, Tesamorelin has an evidence overview, and our tesamorelin cost page breaks down what different vial sizes and pharmacy routes actually run.

Frequently asked questions

What is the correct tesamorelin dosage per day?

The FDA-approved and trial-tested dose is 2mg once daily by subcutaneous injection, generally given in the evening ^[1]. This is the dose used in the phase 3 trials that led to approval for HIV-associated lipodystrophy, and there's no validated higher or lower daily dose backed by comparable trial data.

How do you mix a 2mg tesamorelin vial?

Reconstitute a 2mg vial with about 1mL of bacteriostatic water to get a 2mg/mL concentration, which draws as 100 units on a standard insulin syringe for a full 2mg dose. Some people use 2mL for a gentler 1mg/mL concentration, but that requires drawing double the volume for the same dose.

What's the tesamorelin dosage for bodybuilding?

No dose has been validated for bodybuilding or general fat loss. The 2mg/day regimen comes entirely from HIV-associated lipodystrophy trials measuring visceral fat by CT scan ^{[1] [4]}; peptide reviews for sports medicine and orthopaedic contexts note this off-label gap directly ^{[5] [6] [7]}.

How do you dose a tesamorelin 5mg vial?

A common approach is reconstituting a 5mg vial with 2.5mL of bacteriostatic water to reach 2mg/mL, so a 1mL draw delivers a 2mg dose matching the trial regimen. Always confirm your specific vial's labeled content before relying on this ratio.

How is tesamorelin 10mg dosed compared to smaller vials?

A 10mg vial reconstituted with 5mL of bacteriostatic water also reaches 2mg/mL, so a 1mL draw still equals a 2mg dose. Larger vials mainly reduce cost per dose and reconstitution frequency, not the target daily dose itself.

Can you use a tesamorelin dosage chart to avoid math errors?

Yes, and it's worth doing on paper before drawing anything into a syringe. A chart mapping vial size, dilution volume, and resulting concentration to syringe units removes the most common source of dosing mistakes, which is misjudging concentration after reconstitution.

How often per day is tesamorelin injected?

Once daily, every day, which is the frequency used throughout the phase 3 trials ^[1]. It is not a weekly or every-other-day protocol; spacing doses further apart than studied has no trial data behind it.

Does tesamorelin dosage need to change based on kidney or liver function?

There's no detailed public dose-adjustment schedule for renal or hepatic impairment in the core trial and pharmacokinetic literature reviewed here ^[3]. Anyone with significant kidney or liver disease should have dosing reviewed individually by a prescriber rather than following a standard chart.

What happens if you miss a tesamorelin dose?

There's no published protocol for missed doses since the trials were built around consistent daily dosing ^[1]. The safer default is resuming the normal schedule rather than doubling the next dose, since doubling was never studied.

Is a higher tesamorelin dose more effective for reducing visceral fat?

No trial evidence supports that. The 2mg/day dose is what produced the CT-measured visceral fat reductions in the phase 3 trials ^[1], and there's no dose-response study published showing added benefit, or added safety margin, above that level.

How long does a mixed tesamorelin vial stay good?

Reconstituted tesamorelin should be refrigerated, protected from light, and used within the in-use window stated for your specific product, generally days to a few weeks rather than months. Discard any vial that looks cloudy or discolored regardless of the date.

Is tesamorelin dosage the same for men and women?

The phase 3 trials and pooled safety analyses were conducted primarily in HIV-associated lipodystrophy populations, and the standard 2mg/day dose was the regimen used across the enrolled participants ^{[1] [4]}. Dosage decisions for any specific person should still go through individualized provider review rather than assuming a one-size approach.

Sources

1. Journal of Clinical Endocrinology and Metabolism, 2010 (PMID 20554713): Pooled analysis of two phase 3 double-blind placebo-controlled trials plus safety extension used the 2mg/day subcutaneous tesamorelin regimen and measured visceral adipose tissue reduction by CT scan.
2. Nature Reviews Drug Discovery, 2011 (PMID 21283099): Tesamorelin is a GHRH analogue that stimulates pituitary growth hormone release, developed and approved for reducing excess visceral fat in HIV lipodystrophy.
3. Clinical Pharmacokinetics, 2015 (PMID 25358450): Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects supports consistent drug clearance across populations under the studied daily dosing regimen.
4. PubMed, Tesamorelin review, 2012 (PMID 31644039): Tesamorelin's approved indication and studied use is specific to HIV-associated lipodystrophy with excess abdominal fat.
5. Journal of the American Academy of Orthopaedic Surgeons: Global Research & Reviews, 2026 (PMID 41490200): Review of therapeutic peptides in orthopaedics notes the gap between mechanistic rationale and validated dosing protocols outside originally studied populations.
6. The American Journal of Sports Medicine, 2026 (PMID 41476424): Primer for sports medicine physicians on injectable peptide therapy describes the gap between mechanism and trial-backed dosing in off-label athletic use.
7. Sports Medicine (Auckland, N.Z.), 2026 (PMID 41966639): Review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance states tesamorelin use for muscle gain or performance is off-label extrapolation without dedicated dosing trials.
8. AIDS (London, England), 2017 (PMID 28832410): Visceral fat reduction with tesamorelin correlated with improved liver enzymes in HIV patients.
9. The Lancet HIV, 2019 (PMID 31611038): Randomized double-blind multicenter trial examined tesamorelin's effects on non-alcoholic fatty liver disease in HIV patients using the standard dosing approach.
10. AIDS (London, England), 2021 (PMID 33756511): Tesamorelin improves fat quality independent of changes in fat quantity.
11. AIDS (London, England), 2024 (PMID 38905488): Study evaluated efficacy and safety of tesamorelin in people with HIV on integrase inhibitors, finding the effect profile held up in this updated treatment context.
12. The Journal of Infectious Diseases, 2025 (PMID 39813152): Study examined tesamorelin's effects on neurocognitive impairment in persons with HIV and abdominal obesity.
13. Drugs, 2011 (PMID 21668043): Review of tesamorelin's use in managing HIV-associated lipodystrophy describes the 2mg daily regimen as the basis for approved use.
14. The Annals of Pharmacotherapy, 2012 (PMID 22298602): Review of tesamorelin as a growth hormone-releasing factor analogue for HIV-associated lipodystrophy reinforces the standard daily dosing regimen.
15. BioDrugs, 2011 (PMID 22050344): Spotlight review on tesamorelin in HIV-associated lipodystrophy covers clinical adoption at the studied dosing level.
16. The Journal of Clinical Endocrinology and Metabolism, 2022 (PMID 35137140): Review on approaching patients with lipodystrophy situates tesamorelin within a broader diagnostic and treatment framework for a specific clinical population.
17. Annales d'Endocrinologie, 2012 (PMID 22748602): Lipodystrophy is described as a defined clinical diagnostic syndrome, not a general descriptor of abdominal fat.
18. Obesity Research & Clinical Practice, 2026 (PMID 41545261): Meta-analysis of randomized controlled trials pools body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin at the studied dosing regimen in HIV-associated lipodystrophy.
19. eCFR, 21 CFR 216.23, 503A Bulks List: Federal regulation governs which bulk drug substances, potentially including tesamorelin, pharmacies may use in 503A compounding.
20. eCFR, 21 CFR 216.24, 503B Bulks List: Federal regulation governs which bulk drug substances outsourcing facilities may use in 503B compounding.
21. Cornell Legal Information Institute, 21 U.S.C. 353a: Statute governing pharmacy compounding allows licensed pharmacies to prepare patient-specific formulations under defined conditions.